
Sign up to save your podcasts
Or


In this company introduction, we speak with David Elsley, President & CEO of Cardiol Therapeutics (NASDAQ/TSX: CRDL), a clinical-stage life sciences company focused on developing therapies to address inflammation-driven cardiovascular diseases.
Cardiol’s lead asset, CardiolRx™, is currently in:
We also cover:
Please email me any further questions you have for David. My email address is [email protected].
Click here to learn more about Cardiol Therapeutics.
By KE Report4.3
1212 ratings
In this company introduction, we speak with David Elsley, President & CEO of Cardiol Therapeutics (NASDAQ/TSX: CRDL), a clinical-stage life sciences company focused on developing therapies to address inflammation-driven cardiovascular diseases.
Cardiol’s lead asset, CardiolRx™, is currently in:
We also cover:
Please email me any further questions you have for David. My email address is [email protected].
Click here to learn more about Cardiol Therapeutics.

3,071 Listeners

151 Listeners

146 Listeners

98 Listeners

362 Listeners

269 Listeners

93 Listeners

77 Listeners

374 Listeners

71 Listeners

417 Listeners

81 Listeners

42 Listeners

22 Listeners

155 Listeners